The Food and Drug Administration said Friday it will offer ultra-fast review to three psychedelic drugs being developed to treat mental health conditions, including depression, the latest step by the Trump administration toward possible approval of the experimental treatments.
President Donald Trump signed an executive order last weekend directing the FDA and other federal agencies to speed research and loosen restrictions on psychedelics, a class of hallucinogenic drugs which remain illegal under federal law.
The FDA said it awarded priority review vouchers to two companies studying psilocybin — the active ingredient in magic mushrooms — for hard-to-treat forms of depression. A third company received a voucher for methylone, a drug related to MDMA, for post-traumatic stress disorder. The FDA did not name the companies in a press release announcing the news.
Read this story now for free
To continue reading, sign up for our newsletter and get unlimited access to WABE.org
You can select your preferences for news and local content. We will never share your email address. Learn how your newsletter sign-up will support WABE and Public Media
